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Abstract:  The  impact  of  four  effective  population-based  interventions,  focusing  on 
individual behavioural change and aimed at reducing tobacco-attributable morbidity, was 
assessed  by  modeling  with  respect  to  effects  on  reducing  prevalence  rates  of  cigarette 
smoking, population-attributable fractions, reductions of disease-specific morbidity and its 
cost for Canada. Results revealed that an implementation of a combination of four tobacco 
policy interventions would result in a savings of 33,307 acute care hospital days, which 
translates  to  a  cost  savings  of  about  $37  million  per  year  in  Canada.  Assuming  40% 
coverage rate for all individually based interventions, the two most effective interventions, 
in terms of avoidable burden due to morbidity, would be nicotine replacement therapy and 
physicians’ advice, followed by individual behavioural counselling and increasing taxes by 
10%. Although a sizable reduction in the number of hospital days and accumulated costs 
could be achieved, overall these interventions would reduce less than 3% of all tobacco-
attributable costs in Canada. 
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1. Introduction 
 
Smoking  is  one  of  the  most  important  risk  factors  for  the  burden  of  disease.  Tobacco  use  is 
responsible for high levels of morbidity and mortality. Smoking causes a substantially increased risk of 
mortality from lung cancer, upper aerodigestive cancer, several other cancers, heart disease, stroke, 
chronic respiratory disease and a range of other medical causes [1]. In the developed world in the year 
2000, smoking was reported to be the risk factor with the largest attributable mortality and attributable 
disability adjusted life years (DALYS); specifically, 12.2% of all DALYS were attributed to this risk 
factor [2]. 
The second Canadian Cost Study indicated that the social costs for substance abuse in Canada are 
high, with a cost of $39.8 billion in 2002 [3,4]. The economic costs of tobacco abuse were the highest 
among all substances, with a cost of $17.0 billion, which represented 42.7% of the total substance 
abuse costs in Canada.  
Given the evident overload of tobacco-attributable social burden, tobacco control measures have 
gained  more  importance. The use of cost-effective tobacco control  measures  is the key to further 
reduce the burden of tobacco smoking [5,6]; for the field of substance abuse see [7-9]. Analysis of 
avoidable burden and avoidable costs of tobacco-attributable morbidity in Canada was thus necessary 
in finding such effective measures. 
 
2. Methodology 
 
2.1. Selection of Interventions 
 
The intervention selection was undertaken in two steps: 
1) A collection of evidence for the most common interventions via a search of meta-analyses with a 
special emphasis on Cochrane Reviews; and 2) an expert consultation to select the best fitting types of 
interventions for Canada. 
 
2.2. Methodological Considerations for Statistical Modeling 
 
Based on previous publications [10-12], we decided to model the impact of different interventions 
in terms of burden of disease. This procedure can be justified by the fact that for tobacco abuse (The 
term “abuse” here is used in the economical definition and does not necessarily effect the psychiatric 
definition of DSM-IV)–contrary to alcohol abuse and illicit drugs–the overwhelming majority of direct 
costs materializes in health care [3,13,14].  
The  usual  epidemiological  model,  as  defined  by  burden  of  disease  studies,  especially  on  the 
international  level  [2,15-17],  operates  with  one-dimensional  risk  factors  and  foresees  the  
following steps: Int. J. Environ. Res. Public Health 2009, 6                 
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  Estimation of population disease with sex and age specific population-attributable fractions, in 
the case of tobacco with smoking-attributable fractions (SAF). 
  Based on SAF, tobacco-attributable morbidity expressed in the number of acute care hospital 
days.  
 
2.3. Computing Smoking-Attributable Fractions  
 
The  contribution  of  a  risk  factor to  disease  or mortality,  relative  to  some  alternative  exposure 
scenario (i.e., PAF, defined as the proportional reduction in population disease or mortality that would 
occur  if  exposure  to  the  risk  factor  were  reduced  to  an  alternative  exposure  scenario,  
ceteris paribus [18,19]), is given by the generalized “potential impact fraction” in Equation 1, or its 
discrete version when the exposure variable is categorical [19-21]: 
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RR(x):   relative risk at exposure level x 
P(x):   population distribution of exposure 
P(x):   counterfactual distribution of exposure (often 0 = no exposure for tobacco) 
m:    maximum exposure level 
 
Since most diseases are multifactorial (caused by a multiple number of risk factors), and because 
some  risk  factors  act  through  other  more  proximal  factors,  population-attributable  fractions  for 
multiple risk factors for the same disease can add up to more than 100% [22,23]. For example, some of 
the cardiovascular disease events may be due to a combination of smoking, physical inactivity and an 
inadequate intake of fruits and vegetables (all acting partially through obesity, cholesterol, and blood 
pressure). Such cases would be attributed to all of these risk factors. While the lack of additivity may 
seem problematic initially, multiple-causality offers the opportunity to tailor prevention based on the 
availability and the cost of the interventions. In terms of tobacco interventions, this means that the 
projected morbidity gains will be achieved through constellations, in which some of the gains could 
also be achieved by other interventions; e.g. the morbidity reduction of tobacco taxation on CHD could 
in part be achieved by improving physical fitness in the population. To estimate tobacco-attributable 
morbidity, SAFs were calculated using the discrete version of Equation 1.  
 
2.4. Smoking Risk Relations  
 
As indicated by Equation 1, the calculation of tobacco-attributable morbidity was based on the 
combination  of  relative  risks  (RRs)  and  prevalence  of  exposure.  The  selection  of  tobacco-related 
diseases and causes of morbidity relied on the comprehensive reviews by the International Agency for 
Research on Cancer [24] and the U.S. Government [1]. These reviews consider the following criteria 
in  judgments of causality: consistency,  strength  of association,  specificity, temporality, coherence, Int. J. Environ. Res. Public Health 2009, 6                 
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dose-response,  and  experimental  evidence.  Once  identified,  the  conditions  were  translated  into 
corresponding  International  Classification  of  Diseases  (ICD)  9  and  10  codes.  The  list  of  these 
conditions is reported in Table 1.  
 
Table 1. Tobacco-attributable conditions  included  in this study and relative risks  from 
English et al. [25]. 
Cause of morbidity  ICD 9  ICD10 
RRs  
(Source: [25])  Comments  
FS   CS  
Lip, oral and pharyngeal cancer   140-149  C00- C14  1.76   4.55   RRs for codes: 140-
141, 143-149  
Esophageal cancer   150   C15   1.79   4.01    
Stomach cancer   151   C16   1.11   1.41    
Liver cancer   155   C22   1.07   1.71    
Pancreatic cancer   157   C25   1.15   1.86    
Laryngeal cancer   161   C32   2.86   7.48    
Lung cancer – m   162   C33-C34   6.75   13.0    
Lung cancer – w   -  -  5.07   11.4    
Cervical cancer   180   C53   1.31   1.75   RRs for codes: 180, 
233.1  
Bladder cancer   188   C67   1.66   2.72    
Kidney, other urinary cancer   189   C64-C66, 
C68   1.61   1.64   Renal parenchymal 
carcinoma - 189.0  
Leukemia  204-208   C91-C95   1.21   1.01    
Parkinson disease   332   G20-G21   0.57   0.57    
Ischaemic heart disease <65   410-414   I20-I25   1.45   3.06    
Ischaemic heart disease - m 65+   -  -  0.93   1.67    
Ischaemic heart disease - w 65+   -  -  1.22   1.67    
Other heart diseases   390-398, 415-
417, 420-429  
I00-I09, I26-
I51   NA   NA    
Cerebrovascular disease <65   430-438   I60-I69   1.30   3.12    
Cerebrovascular disease 65+   -  -  1.15   1.65    
Atherosclerosis   440   I70   NA   NA    
Other arterial diseases   441-448   I71-I78   NA   NA    
Atherosclerosis and other arterial 
diseases   440-448   I70-I78    1.82   2.54    
Pneumonia   480-487   J10-J18   1.29   1.47    
Bronchitis, emphysema   490-492   J40-J43   NA   NA    
Chronic airways obstruction   496   J44   NA   NA    
COPD    490-492, 496   J40-J44   6.70   9.80    
Peptic ulcer   531-534   K25-K27   2.24   2.07    
Crohn disease – m  555   K50   1.92   1.92    
Crohn disease – w   -  -  1.60   3.27    
Ulcerative colitis   556   K51   1.71   0.63    
Fire injury   E890-E899   X00-X09   NA   NA   TAF = 23%  
M–men; W–women 
FS–former smokers; CS–current smokers 
 
The RRs were abstracted from a comprehensive review of the determinants of health prepared by 
the Australian Government, which contained systematic meta-analyses of the health effects of tobacco Int. J. Environ. Res. Public Health 2009, 6                 
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smoking [25]. The RRs  for ex-smokers and current smokers are  listed  in Table 1. The SAFs  for 
morbidity were calculated by combining the RRs with the exposure prevalence.  
 
2.5. Prevalence of Smoking in Canada  
 
Smoking prevalence for different levels of smoking consumption for Canada, as a whole, were 
obtained from the Canadian Community Health Survey 2003 (CCHS cycle 2.1), a population based 
representative survey conducted by Statistics Canada [26]. All prevalence estimates were sex- and age 
group-specific. However, the categorization of smoking status varied by specified disease and were 
based on the RRs available in the meta-analyses. For each disease, for which the identified meta-
analysis included dose-response-specific RR, prevalence estimates were also dose-specific (e.g., never, 
former, current, 1-14, 15-24, 25+ cigarettes per day). Current smokers, those who reported occasional 
smoking or daily smoking, were further categorized by the number of cigarettes smoked per day, when 
sufficient information existed to do so. 
In order to model smoking behaviour in Canada with pressure towards reducing smoking rates, we 
assumed a scenario  based on the  literature; e.g. trends observed  in regions of North America and 
Australia featuring intense efforts to reduce tobacco related harm. These scenarios were based on the 
following (see also [27]): 
  Yearly quitting rates of 10%; 
  The assumption that 80% of smokers wanted to quit; 
  The assumption of an annual incidence rate (new cases of smokers before and after intervention 
in the specified year) of 0.46% for current female non-smokers, and prevalence proportionate 
incidence rate for males. 
 
2.6. Morbidity Data  
 
The  number  of  acute  care  hospital  days  in  Canada  for  2002  was  obtained  from  the  Canadian 
Institute for Health Information (CIHI), on the national and the provincial level according to ICD-10 
codes. The national level data was composed of only seven provinces and two territories (Alberta, 
British Columbia, Newfoundland, Northwest Territories, Nova Scotia, Ontario, Prince Edward Island, 
Saskatchewan,  and  Yukon  Territory).  For  the  national  level,  data  was  provided  for  each  disease 
condition, as well as for each sex and age 20+. Based on these figures, the data for Canada, as a whole, 
were estimated using the total population: the disease-specific rate of occurrence observed in the data 
provided was applied to the total population of Canada to obtain the estimated number of disease-
specific occurrences.  
The  Hospital  Morbidity  Database  (HMDB),  held  by  CIHI,  captures  information  on  patients 
separated through discharge or death  from acute care  facilities  in Canada. This database provides 
national data on acute care hospitalizations by diagnoses and procedures excluding day procedures 
(e.g., day surgeries), outpatient, and emergency department visits. The HMDB also includes data on 
newborns  but not stillborns and cadaveric donor  “discharges”.  Also to note, figures are  based on 
facility geography, that is, where the hospital is located, thus possible non-Canadians may be included. 
Additionally, the statistics reflect the number of hospitalizations, which is somewhat higher than the Int. J. Environ. Res. Public Health 2009, 6                 
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number  of  individuals  diagnosed  since  individuals  with  multiple  admissions  during  a  single  year 
would be counted more than once.  
The number of hospital days (i.e., length of stay) is associated with the condition coded as Most 
Responsible Diagnosis (MRD) on the patient’s hospital record. This means that the MRD accounts for 
the  most of the days a patient stays  in a  hospital.  A diagnosis of  MRD  is described as the  most 
significant condition of the patients’ that is responsible for his/her stay in the hospital. When multiple 
diagnoses are classified as the most responsible, coders are instructed to code the diagnosis responsible 
for the longest length of stay [28]. As the hospital days based on the MRD may overlap in cases with 
more than one MRD, the calculated hospital days had to be adjusted to the overall hospital days in 
Canada. This  adjustment  implied a province-specific application of a  shrinkage  factor, derived  by 
dividing  the  number  of  hospital  days  in  a  province  by  the  number  of  MRD  hospital  days  in  the  
same province. 
 
2.7. Estimating Avoidable Morbidity and Its Cost 
 
The baseline scenario costs of acute care hospitalizations were estimated by multiplying the SAF 
for conditions known to be affected or caused by tobacco smoking by the aggregate number of acute 
care hospital days for each condition by age and sex. These figures were then multiplied by the per 
diem cost of acute care hospital days, by condition and by province or territory, using costs obtained 
from  a  variety  of  sources  (Table  2,  [3,29]).  The  total  national  figures  were  then  calculated  by 
aggregating the total costs due to tobacco-attributable conditions across provinces and territories. 
 
Table 2. Total cost per night in acute care hospital per province and territory, and Canada, 2002.  
Provinces  Average cost per night $ 
Alberta  1,311 
British Columbia  1,524 
Manitoba  1,346 
New Brunswick  1,284 
Newfoundland  1,455 
Nova Scotia  1,217 
Ontario  1,045 
Prince Edward Island  798 
Quebec  990 
Saskatchewan  1,263 
Northwest Territory  2,177 
Nunavut  SUB 
Yukon Territory  883 
CANADA  1,109 
SUB = substitution (average cost of Northwest Territories was substituted) 
 
To compute the avoidable costs of the interventions related to acute care hospital days, we applied 
the estimated percentage changes in the SAF caused by the intervention for each tobacco-attributable Int. J. Environ. Res. Public Health 2009, 6                 
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condition to the baseline figures. We, thereby, obtained the changes in costs for all tobacco-attributable 
conditions, which were then aggregated to provide the estimated avoidable cost of each intervention. 
 
3. Results 
 
3.1. Collection of Evidence for Most Common Interventions 
 
Fifty-one  systematic reviews were  found with respect to the effectiveness of  specific smoking-
related  interventions.  Seven  experts  were  contacted  to  identify  four  evidence-based  intervention 
strategies to reduce tobacco-attributable morbidity in Canada. As a result, the following interventions 
were selected based on the feedback of the experts: 
 
a) Public policy interventions: 
 
1) Price increase 
There is a strong link between the price of cigarettes and its consumption: increases in the cost of 
cigarettes to the consumer will decrease consumption rates and, therefore, decrease tobacco-related 
problem rates. 
 
b) Interventions focusing on individual behavioural change (counselling, brief advice, therapy): 
 
2) Individual behavioural counselling (IBC) for smoking cessation 
IBC was defined as a face-to-face encounter between a smoking patient and a counsellor trained in 
assisting  smoking cessation. This excludes counselling delivered  by doctors and nurses  as part of 
clinical care. 
 
3) Nicotine replacement therapy (NRT) for smoking cessation 
NRT  included  chewing  gum,  transdermal  patches,  nasal  spray,  inhalers  (a  cigarette-like  device 
which delivers nicotine to the buccal mucosa by sucking) and tablets or lozenges. 
 
4) Physician advice for smoking cessation 
Physician advice to stop smoking was defined as verbal instructions from the physician with a ’stop 
smoking’ message irrespective of whether or not information was provided about the harmful effects 
of smoking. Advise as part of multifactorial lifestyle counselling (e.g., including dietary and exercise 
advice)  was  excluded.  Therapists  were  physicians,  or  physicians  supported  by  another  
healthcare worker. 
 Int. J. Environ. Res. Public Health 2009, 6                 
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Table 3 provides a summary of the effectiveness of the selected interventions. 
 
Table 3. Interventions and their effectiveness. 
Type of intervention  Effect  Reference 
Public policy interventions 
Taxation and price increases  2% prevalence reduction in smokers 
associated with 10% increase in price, based 
on meta-analysis for high income countries. 
[30] 
Interventions focusing on individual behavioural change 
Individual behavioural counselling 
for smoking cessation (non-medical) 
Cessation ratio of 1.56 (95% CI: 1.32–1.84) 
compared to controls without intervention 
[31] 
Nicotine replacement therapy for 
smoking cessation 
Cessation ratio of 1.58 (95% CI: 1.50–1.66) 
compared to controls without intervention 
[32] 
Physician advice for smoking 
cessation 
Cessation ratio of 1.66 (95% CI: 1.42–1.94) 
compared to controls without intervention 
[33] 
 
3.2. Exposure 
 
Figure 1 provides an overview of exposure to smoking in Canada by sex and age. As expected, men 
smoked more than women on average, and smoking prevalence decreased with age. 
 
Figure 1. Prevalence in percentage of different smoking categories by gender and age in 
Canada in 2002. 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
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Never smokers
Male Female
Former smokers
Male Female
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smokers
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Overall (All ages)
20-44 years
45-64 years
65+ years
 
Source: Canadian Community Health Survey (CCHS) 2003 [26] 
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3.3. Tobacco-Attributable Morbidity in Canada 2002 
 
Overall, 1,408,252 hospital days were estimated to be attributable to tobacco (815,059 for men and 
593,193 for women) in Canadian population over 20 years old in 2002. This constitutes 6.6% of all 
hospital days in acute care hospitals in Canada (men: 8.5%; women: 5.0%). 
The two single disease  categories  ischaemic  heart disease (IHD)  and  lung  cancer  made up the 
majority  of  tobacco-attributable  acute  care  hospital  days  -  about  40%  (35.9%  in  men,  45.3%  in 
women). Specifically, IHD accounted for 25% of the total tobacco-attributable hospital days (350,793 
hospital days;  men: 173,418; women: 177,375). The  next  largest single  category was  lung cancer 
(15%; 209,627 hospital days, men: 118,788, women: 90,839). 
 
3.4. Effectiveness of Interventions 
 
Table  4  translates  the  effects  of  selected  interventions  into  the  common  metric  of  smoking 
prevalence  rates  in  the  Canadian  adult  population  (operationalized  as  all  inhabitants  15  years  
and older). 
 
Table 4. Detailed results of effectiveness of different interventions for smoking cessation 
on prevalence of smoking in Canada (2002). 
Overall (all ages >15 )  15-19 Yrs  20-44 Yrs  45-64 Yrs  65+ Yrs 
       M %  W %  M %  W %  M %  W %  M %  W %  M %  W % 
Natural course plus quitters plus new beginners = baseline scenario     
NS  29.1  40.4  58.3  59.2  32.4  38.7  20.8  34.2  18.8  47.6 
FS  44.6  37.8  20.0  18.6  35.1  35.3  54.7  44.1  69.7  41.9 
CS  26.3  21.8  21.8  22.2  32.5  26.0  24.5  21.7  11.5  10.5 
  100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0 
Taxation change to result in price increases of 10%         
FS  45.1  38.2  20.4  19.0  35.8  35.8  55.2  44.5  69.8  42.2 
CS  25.8  21.4  21.3  21.7  31.8  25.5  24.0  21.3  11.4  10.2 
      100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0 
Individual behavioural counselling (assuming 40% coverage based on those willing to quit)   
FS  45.2  38.3  20.5  19.0  35.9  35.9  55.3  44.6  69.9  42.2 
CS  25.7  21.3  21.3  21.7  31.7  25.4  23.9  21.1  11.3  10.2 
      100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0 
NRT (assuming 40% coverage based on those willing to quit)       
FS  45.4  38.5  20.6  19.3  36.2  36.1  55.5  44.9  70.0  42.4 
CS  25.4  21.1  21.1  21.5  31.4  25.2  23.7  20.9  11.2  10.1 
      100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0 
Physician's advice (assuming 40% coverage based on those willing to quit)     
FS  45.4  38.5  20.6  19.2  36.1  36.1  55.5  44.9  70.0  42.4 
CS  25.5  21.1  21.1  21.5  31.5  25.2  23.7  20.9  11.2  10.1 
      100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0 
NS–Never smokers 
FS–Former smokers 
CS–Current smokers 
M–men; W–women 
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3.5. Avoidable Morbidity and Its Cost in Canada 
 
Table 5 shows the effectiveness of interventions on morbidity, measured as acute care hospital days, 
in  Canada.  The  results  revealed  that  an  implementation  of  the  four  aforementioned  interventions 
related to tobacco policy combined would result in a savings of 33,307 acute care hospital days.  
 
Table 5. Interventions and their impact on tobacco-attributable acute hospital days (all 
cause), 20+ years in Canada (2002). 
All cause 
20-44 Yrs  45-64 Yrs  65+ Yrs  20+ Yrs       
M  W  M  W  M  W  M  W  Total       
Natural course 
plus quitters plus 
new beginners = 
baseline scenario  27,789  11,155  241,401  88,257  545,869  493,782  815,059  593,193  1,408,252 
     
Various Intervention Scenarios 
Tobacco-attributable 
acute hospital days saved 
M  W  Total 
Taxation change 
to result in price 
increases of 10% 
27,635  11,102  240,316  87,898  543,801  491,614  811,753  590,614  1,402,367  3,306  2,579  5,885 
IBC* 
27,613  11,091  240,098  87,808  542,765  491,614  810,477  590,513  1,400,990  4,582  2,680  7,262 
NRT*  
27,546  11,069  239,661  87,627  541,729  490,528  808,936  589,225  1,398,161  6,123  3,968  10,091 
PA* 
27,569  11,069  239,661  87,627  541,729  490,528  808,958  589,225  1,398,183  6,101  3,968  10,069 
ALL: taxation, 
IBC, NRT, PA  
-  -  -  -  -  -  -  -  -  20,111  13,196  33,307 
                         *assuming 40% coverage based on those willing to quit 
IBC–Individual behavioural counselling 
NRT–Nicotine replacement therapy 
PA–Physician's advice 
M–men; W–women 
Numbers may not add up because of rounding (all numbers are based on 
smoking attributable fractions and thus have decimals) 
 
This would result in cost savings of about $37 million in Canada per year (Table 6). 
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Table  6.  Net  savings  of  tobacco-attributable  cost  (CND  $)  due  to  implementation  of 
selected interventions in Canada (2002). 
Selected Interventions  M  W  TOTAL 
Baseline  903,900,431  657,851,037  1,561,751,468 
Taxation change to result in price increases of 10%  900,234,077  654,990,926  1,555,225,003 
Difference between baseline and this intervention*  3,666,354  2,860,111  6,526,465 
Relative change between baseline and this intervention  0.4%  0.4%  0.4% 
IBC (assuming 40% coverage based on those willing to quit)  898,818,993  654,878,917  1,553,697,910 
Difference between baseline and this intervention*  5,081,438  2,972,120  8,053,558 
Relative change between baseline and this intervention  0.6%  0.5%  0.5% 
NRT (assuming 40% coverage based on those willing to quit)  897,110,024  653,450,525  1,550,560,549 
Difference between baseline and this intervention*  6,790,407  4,400,512  11,190,919 
Relative change between baseline and this intervention  0.8%  0.7%  0.7% 
PA (assuming 40% coverage based on those willing to quit)  897,134,422  653,450,525  1,550,584,947 
Difference between baseline and this intervention*  6,766,009  4,400,512  11,166,521 
Relative change between baseline and this intervention  0.7%  0.7%  0.7% 
Difference between baseline and all interventions  22,304,208  14,633,255  36,937,463 
Relative change between baseline and all interventions  2.5%  2.2%  2.4% 
*Avoidable cost 
IBC–Individual behavioural counselling 
NRT–Nicotine replacement therapy 
PA–Physician's advice 
M–men; W–women 
 
The  most  effective  intervention  in  terms  of  avoidable  burden  due  to  morbidity  was  nicotine 
replacement therapy and physician’s advice (savings more than $11 million per each intervention, 60% 
of total savings), followed by individual behavioural counselling (more than $8 million per year, 22% 
of total savings) and increasing taxes (more than $6.5 million per year, 18% of total savings; Tables 5, 
6 and Figure 2).  
 
Figure 2. Interventions and their impact on tobacco-attributable acute hospital days (all 
cause), 20+ years in Canada (2002). 
Taxation 
increases
18%
IBC
22%
NRT
30%
PA
30%
 
IBC–Individual behavioural counselling 
NRT–Nicotine replacement therapy 
PA–Physician's advice 
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Additionally, this study estimated the effect of the interventions on the burden and the cost of two 
of the biggest contributors: IHD and lung cancer. The results revealed that an implementation of the 
four interventions related to tobacco policy combined would result in a savings of 20,264 acute care 
hospital days due to IHD and 1,052 acute care hospital days due to lung cancer in Canada. This would 
result in cost savings of about $22.5 million (57% of total savings) for IHD and more than $1.2 million 
for lung cancer in Canada per year.  
 
3.6. Limitations and Conclusion of the Study 
 
This study has several limitations. First, the effects of all interventions were modeled as if they 
occurred  instantaneously,  therefore  the  combined  effect  of  four  interventions  is  possibly 
overestimated. In addition, the study did not estimate over what periods of time that these benefits in 
morbidity  and  cost  would  be  achievable.  Furthermore,  the  choice  of  implementing  a  single 
intervention  or  combined  interventions  serves  as  lower  and  upper  estimates,  respectively,  for  
this study.  
The study also overestimates the effects on chronic health conditions that are solely attributable to 
tobacco. For example, if some intervention could reduce tobacco consumption to zero at a certain point 
in  time,  tobacco-related  disease  burden  would  not  be  zero  immediately  thereafter.  Instead,  some 
burden of disease would persist due to previous tobacco consumption. For instance, there will be some 
people already having tobacco-attributable lung cancer and some people may even develop new lung 
cancer or other cancer in the future based on their past tobacco exposure. 
The study also did not take into consideration the effects of the ongoing interventions aimed to 
prevent multifactorial diseases such as cardiovascular diseases and cancer. 
In addition, current estimates of avoidable acute care hospital days due to tobacco use and its cost 
do not reflect the rates of return that the society might achieve. In order to compute the potential rates 
of return on expenditure, it is necessarily to conduct a cost benefit analysis. 
In this study only four exemplary interventions were modeled as a demonstration of the possibility 
of  improving  population  health  and  saving  public  health  expenditures  associated  with  tobacco 
smoking. There are many more effective population-based intervention and interventions focusing on 
individual  behavioural  change  which  would  further  reduce  tobacco-attributable  burden  and  its 
associated costs. It is our hopes that this study can positively influence the decision making on tobacco 
control in Canada. 
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